Viberzi and Dexilant drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Viberzi and Dexilant. Common interactions include pain among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people who take Viberzi and Dexilant have. It is created by eHealthMe based on reports of 47 people who take Viberzi and Dexilant from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 12, 2023

47 people who take Viberzi and Dexilant together, and have interactions are studied.

What is Viberzi?

Viberzi has active ingredients of eluxadoline. eHealthMe is studying from 2,817 Viberzi users for its effectiveness, alternative drugs and more.

What is Dexilant?

Dexilant has active ingredients of dexlansoprazole. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 52,273 Dexilant users for its effectiveness, alternative drugs and more.

Number of Viberzi and Dexilant reports submitted per year:

Common Viberzi and Dexilant drug interactions by gender *:

female:

Pain
Dyspnoea
Fall
Anxiety
Renal failure
Dizziness
Foot fracture
Hypertension
Alopecia
Ankle fracture

male:

Diarrhoea
Pancreatitis acute
Sinus congestion
Skin ulcer
Arthralgia
Drug hypersensitivity
Fatigue
Hyperhidrosis
Muscular weakness
Oral pain

Common Viberzi and Dexilant drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Infection
Neoplasm malignant
Pain
Swelling

30-39:

n/a

40-49:

Vomiting
Anxiety
Chronic kidney disease
Nephrogenic anaemia
Renal failure
Renal tubular necrosis
Tubulointerstitial nephritis
Injection site extravasation
Injection site nerve damage
Limb discomfort

50-59:

Drug hypersensitivity
Pain
Pancreatitis
Sphincter of oddi dysfunction
Abdominal discomfort
Abdominal distension
Abdominal pain upper
Alopecia
Amnesia
Anxiety

60+:

Arthralgia
Ankle fracture
Oedema peripheral
Pain
Diarrhoea
Palpitations
Bronchitis
Heart rate irregular
Hypertension
Loss of consciousness

Common conditions people have *:

Irritable Bowel Syndrome: 19 people, 40.43%
Pain: 8 people, 17.02%
Diarrhea: 6 people, 12.77%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 10.64%
Multiple Myeloma (cancer of the plasma cells): 5 people, 10.64%
Thyroid Diseases: 4 people, 8.51%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 8.51%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 4 people, 8.51%
Basedow's Disease (autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones): 4 people, 8.51%
Hypersensitivity: 4 people, 8.51%

* Approximation only. Some reports may have incomplete information.

Do you take Viberzi and Dexilant?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.